A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study)
Phase of Trial: Phase II
Latest Information Update: 07 Oct 2019
Price : $35 *
At a glance
- Drugs Irinotecan (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Acronyms NEO-Nal- IRI Study
- 01 Oct 2019 Planned number of patients changed from 53 to 28.
- 20 Jun 2019 Planned number of patients changed from 28 to 53.
- 19 Jan 2019 Study design was presented at the 2019 Gastrointestinal Cancers Symposium.